First of all, please excuse some typos a as I am blind and still learning to edit out mistakes.
Soggy, you just might be on to something with the dual therapy confabulations to the patent office, but...
IMHO, AVXL don't need any stinkin patent.
They got five years of protection out of the gate for exclusive use per FDA and similar rules in the EU.
Meanwhile , they get six more months for each indication they test up to a NDA decision, even if negative.
I believe that only pediatric applications count,. Maybe someone here could figure out just how many pediatric neuro diseases there are, not to mention diseases in other organs that might benefit from A273. Could it be fourty different syndromes maybe. That would give us 25 years. In the USA and similar time in the EU, assuming there is a EU.
Past 25 years, the present value does not make much difference.
Big pharma uses this little trick all the time. They are raking it in on many drugs way past the original patent.
Maybe someone could do some DDexamples for us.
So one more time...
We don't need no stinkin patents.
and yeah Adam, I am just stupid retail ready to be fleeced., but watch out, sometimes the sheep bite.